July 15, 2022

IAVI to participate in the 24th International AIDS Conference beginning July 29 in Montreal, Canada, and virtually

IAVI at AIDS 2022 homepage

IAVI is proud to participate in AIDS 2022 hosted by the International AIDS Society (IAS). The conference will feature updates in HIV science, indigenous responses to HIV, youth-led initiatives, surveillance ethics, health innovation, mental health, equitable product rollout, HIV cure and vaccine research, and much more. We are eager to join in celebrating the progress made by scientists, advocates, and communities, and to engage in discussions and deliberations on how we will achieve a world without AIDS.

Below are the ways we are contributing to AIDS 2022, together with our partners. Learn more about the conference and register here to access conference presentations. And while the conference is happening, follow along on IAVI's social media channels for updates and a window into the live event at #AIDS2022.

We gratefully acknowledge the funders whose generous support enables the IAVI and partner work being showcased at AIDS 2022.

 

Satellite, Symposium, and Oral Abstract Sessions

Thursday, July 28, 11:30 - 12:30 EDT

Pre-conference session: Future Leaders in HIV Economics: Assessing Equity, Cost-Effectiveness, Research Gaps and Policy Uptake in HIV Prevention

Presentation title: Biomedical prevention technologies: identifying gaps and proposing priorities for future research, Sergio Torres-Rueda, research fellow in health economics, London School of Hygiene and Tropical Medicine, France

Code PC32, Live (in-person)

IAVI author: Shelly Malhotra, executive director of Global Access, IAVI, United States

 

Friday, July 29, 14:45 - 16:15 EDT

Satellite session: Experimental medicine trials in Africa: ethical considerations and community engagement

Introduction: Robin Shattock, professor of mucosal infection and immunity, Imperial College London, United Kingdom

Code SA02301, Live (in-person)

Presentation title: Experimental Medicine Vaccine Trials, Kundai Chinyenze, executive medical director, IAVI, United Kingdom

Code SA02302, Live (hybrid)

Panel discussion: Eunice Nduati, principal investigator, KEMRI | Wellcome Trust, Kenya

Code SA02304, Live (in-person)

 

Friday, July 29, 14:45 - 16:15 EDT

Satellite session: Africa HIV cure research: Strengthening industry-community engagement in clinical research

Presentation title: How clinical research is involving communities, Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SA02705, Pre-recorded by the speaker

Panel discussion and Q&A: Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SA02707, Live (in-person)

 

Saturday, July 30, 8:00 – 9:00 EDT

Satellite session: Will mRNA lead to a long-awaited HIV vaccine?

Presentation title: IAVI/Moderna studies (G001, G002, G003), William Schief, executive director of vaccine design, IAVI’s Neutralizing Antibody Center (NAC), United States

Code SA04602, Live (hybrid)

Panel discussion: Julien Nyombayire, research physician, Center for Family Health Research, Rwanda

Code SA04605, Live (in-person)

 

Sunday, July 31, 14:15 – 15:15 EDT

Symposium: Combining immunotherapeutic agents to achieve ARV-free remission of HIV

Session track: Track A: Basic and translational science, Thumbi Ndung’u, scientific director, University of KwaZulu-Natal HIV Pathogenesis Programme (HPP), South Africa

Code SY20, Live (hybrid)

 

Sunday, July 31, 14:15 – 15:15 EDT

Symposium: Antibodies for HIV prevention: The path forward

Introduction: Introductory notes on why we need to consider mAbs as a potential tool for HIV prevention, Shelly Malhotra, executive director of Global Access, IAVI, United States

Presentation title: Can we design, develop and manufacture antibodies that are effective, affordable and easy to deliver? Evidence from the pipeline, Devin Sok, vice president of discovery and innovation, IAVI, United States

Code SY21, Live (hybrid)

 

Monday, August 1, 14:15 – 15:15 EDT

Oral abstract session and Q&A: Optimizing investments for health: Cash, cost and prices

Presentation title: Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settings, Caitlin M. Dugdale, infectious disease physician and research fellow, Massachusetts General Hospital, Medical Practice Evaluation Center, United States

Code OAE03, Live (hybrid)

IAVI authors: Shelly Malhotra, executive director of Global Access, IAVI, United States and Vincent Muturi-Kioi, medical director, IAVI, Kenya

 

Global Village

If you are attending the conference, the Global Village will be a great place to visit to broaden your networks, engage in exhibits, and learn from community led initiatives addressing AIDS. The Global Village will host speaker sessions, cultural activities, live performances, film screenings, art exhibitions, and more.

 

Posters

Additionally, many researchers are representing IAVI, ADVANCE, and partners in the posters listed below.

TitlePresenterType
Consequences of HIV-1 Gag-protease driven replication capacity for cellular inflammation and HIV-1 cell-to-cell transmission Omolara O. Baiyegunhi, University of KwaZulu-Natal, South Africa E-poster
Lessons from COVID-19 on the use of digital tools to support HIV service uptake and community engagement in research: Voices from India. Devi Leena Bose, IAVI, India E-poster
Cross-sectional analysis reveals limited genetic diversity in genes that affect integration site targeting (Integrase and Capsid) in acute HIV-1 subtype C infection in South Africa Tatenda Jimmy Blessing Chikowore, University of KwaZulu-Natal, South Africa E-poster
Broadly neutralizing antibodies - A new hope for elimination of vertical transmission of HIV Lusine Ghazaryan, U.S. Agency for International Development, United States E-poster
Understanding the lived experiences of people at the intersection of HIV and COVID-19. Anhad Hundal, IAVI, India Poster exhibition
Trust, Respect and Reciprocity underlie the preferred ways of community engagement in HIV biomedical research: Findings from a qualitative investigation in India Vijayalakshmi Loganathan, C-SHaRP, India E-poster
Perspectives and Preferences for multi-purpose prevention technologies (MPTs) to address sexual and reproductive health (SRH) needs among adolescent girls and young women (AGYW) in Kenya and Uganda Laura Lusike Lunani, KAVI Institute of Clinical Research, Kenya Poster exhibition
Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention: A qualitative investigation among Adolescent Girls and Young Women (AGYW) in India Vaishali S. Mahendra, C-SHaRP, India E-poster
Effect of human immunodeficiency virus type 1 (HIV-1) subtype C transactivator of transcription (Tat) P21A variant on nuclear levels of active positive transcription elongation factor b (P-TEFb). Zakithi Mkhize, University of KwaZulu-Natal, South Africa E-poster
Using a three-layered approach to understand the needs for effective community engagement in HIV biomedical research in India – Perspectives from community representatives, implementing researchers and domain experts Joyeeta Mukherjee, IAVI, India E-poster
Female genital schistosomiasis and STI prevalence among at-risk women for HIV in Zambia Sepo Mwangelwa, Center for Family Health Research, Zambia E-poster
Female sex workers' preferences for Multi-Purpose Technologies to prevent HIV, other Sexually Transmitted Infections and unintended pregnancies in Kampala, Uganda Stella Namukwaya, MRC/UVRI Uganda Research Unit on AIDS, Uganda Poster exhibition
HIV-1 subtype C Vif transmitted/founder (T/F) variants preferentially degrade APOBEC3G over APOBEC3F Nicole Reddy, University of KwaZulu-Natal, South Africa E-poster

Media Contacts

Africa

Ethel Makila
+254 71 904 3142
EMakila@iavi.org 

 

Europe

Hester Kuipers
+31 20 521 0343
HKuipers@iavi.org 

 

India

Devi Leena Bose
+91 11 4737 6031
DLeena@iavi.org 

 

North America

Rose Catlos
+1 212 847 1049
RCatlos@iavi.org